Shanghai, China (19th December 2021) – DFE Pharma, a global leader in pharmaceutical excipient solutions, has launched a Virtual Booth for the Chinese market to interact, connect and share experiences with its partners and customers. From December 20th to December 30th , visitors can attend this virtual experience to learn more about DFE Pharma’s portfolio in Biopharma, Inhalation and Oral Solutions Dose as well as the company latest innovation approaches including continuous manufacturing and 3D printing.
The Virtual Booth contents are available in Mandarin and English. Once registered, visitors access to a variety of assets like product information, expert sessions and other videos and can get in contact with DFE Pharma’s China team. This new approach aligns with the company’s effort to stay connected with their customers, even during these challenging times, overcoming pandemic barriers.
“At DFE Pharma, we always strive to offer our customers with premium excipients and services, which include maintaining close contact with them to meet their requirements in a fast pace while assuring high product quality and supply reliability” explains Bas van Driel, CEO of DFE Pharma. “As a key market for us, we are proud to launch this new way to connecting with our partners in China, sharing how we can contribute to their success and carefully listening to their needs”.
As the world’s second largest healthcare market, China pharmaceutical landscape is moving fast to develop new best-in-class treatments for those patients’ with unmet needs, not only in-country but globally. Chinese biopharma companies are accelerating their pipeline and portfolio through national investments and key partnerships with Europe and USA based companies, and achieving a growing number of regulatory approvals, also abroad.
Within this landscape and beyond this Virtual Booth, DFE Pharma is reinforcing its position in China and the rest of Asia with continuous investments to expand its capabilities in the region. During 2021, the company has established its own warehouse in the country, specifically in Shanghai, and implemented a new SAP system, enabling to support local customers and provide them with an even more reliable security of supply.
“From our leadership position in the excipients landscape in China, we look forward to putting in place further services and products to our local customers with strong local regulations support. And our new warehouse and SAP system is already enhancing our Chinese customers to better access to our portfolio of over 200 solutions, from Oral Solid Dose to Inhalation, without forgetting our new Biopharma portfolio” highlighted Sharon Shen, General Manager DFE Pharma China.
Follow us on WeChat:
